Impact BioMedical, INC. Increase (Decrease) in Accrued Liabilities
Impact BioMedical, INC. (IBO) reported Increase (Decrease) in Accrued Liabilities of $54.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-07
- Impact BioMedical, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $38.00K, a 35.59% decline year-over-year.
- Impact BioMedical, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $16.00K, a 33.33% increase year-over-year.
- Impact BioMedical, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$142.00K, a 252.69% decline year-over-year.
- Impact BioMedical, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $69.00K, a 68.29% increase year-over-year.
- Impact BioMedical, INC. increase (decrease) in accrued liabilities for fiscal 2025 was -$2.00K.
- Impact BioMedical, INC. increase (decrease) in accrued liabilities for fiscal 2024 was -$35.00K, a 120.96% decline from fiscal 2023.
- Impact BioMedical, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $167.00K, a 192.98% increase from fiscal 2022.
- Impact BioMedical, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $57.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $54.00K 10-Q · filed 2026-08-07 | -$88.00K derived: sum of 3 quarters · filed 2026-08-07 | -$19.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $16.00K 10-Q · filed 2026-05-12 | -$126.00K derived: sum of 2 quarters · filed 2026-05-12 | -$57.00K derived: sum of 3 quarters · filed 2026-05-12 | $2.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$73.00K derived: sum of 2 quarters · filed 2026-03-11 | -$14.00K derived: sum of 3 quarters · filed 2026-08-07 | -$2.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $128.00K derived: sum of 2 quarters · filed 2026-08-07 | $140.00K 10-Q · filed 2025-11-07 | $233.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $71.00K 10-Q · filed 2026-08-07 | $164.00K derived: sum of 3 quarters · filed 2026-08-07 | $205.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $12.00K 10-Q · filed 2026-05-12 | $105.00K derived: sum of 2 quarters · filed 2026-05-12 | $146.00K derived: sum of 3 quarters · filed 2026-05-12 | $160.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $134.00K derived: sum of 2 quarters · filed 2026-03-11 | $148.00K derived: sum of 3 quarters · filed 2026-03-11 | -$35.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $55.00K derived: sum of 2 quarters · filed 2025-11-07 | -$128.00K 10-Q · filed 2025-11-07 | $96.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$169.00K 10-Q · filed 2025-08-14 | $55.00K derived: sum of 3 quarters · filed 2025-08-14 | $61.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$183.00K 10-Q · filed 2025-05-14 | $41.00K derived: sum of 2 quarters · filed 2025-05-14 | $47.00K derived: sum of 3 quarters · filed 2025-05-14 | -$3.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $224.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $230.00K derived: sum of 2 quarters · filed 2025-03-28 | $180.00K derived: sum of 3 quarters · filed 2025-03-28 | $167.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$44.00K derived: sum of 2 quarters · filed 2024-11-12 | -$57.00K 10-Q · filed 2024-11-12 | -$6.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$63.00K 10-Q · filed 2024-08-13 | -$12.00K derived: sum of 3 quarters · filed 2024-08-13 | -$5.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$13.00K 10-Q · filed 2024-05-10 | $38.00K derived: sum of 2 quarters · filed 2024-05-10 | $45.00K derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $58.00K derived: sum of 2 quarters · filed 2024-02-20 | $57.00K 10-K · filed 2024-02-20 | |
| 2022-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $6.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$1.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |